Тема недоступна
Огляд
Select a topic to solve related cases or follow a course topic
-
Topic 1UPDATED --- Targeted therapies for metastatic UCa in special populations
-
Topic 2Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 3Finding the right ADT for the right patient
-
Topic 4High-risk non-metastatic prostate cancer
-
Topic 5Management of non-metastatic castration-resistant prostate cancer
-
Topic 6NEW --- Treatment selection in mCRPC patients harbouring HRR gene mutations
-
Topic 7NEW --- Sequencing treatments in mCRPC patients without HRR gene mutations
-
Topic 8High-risk non-metastatic prostate cancer
-
Topic 9Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 10Finding the right ADT for the right patient
-
Topic 11UPDATED --- First-line therapy of synchronous and metachronous metastatic UCa
-
Topic 12New hope for patients progressing after prior treatment for mUCa
-
Topic 13Handling AEs of targeted therapies for metastatic UCa
-
Topic 14Molecular diagnostics in the era of targeted therapies for mUCa
-
Topic 15Adjuvant treatment approaches for MIBC
-
Topic 16Histological subtypes of (N)MIBC: managed differently compared to pure UCa?
-
Topic 17Initial treatment of MIBC
-
Topic 18Follow-up surveillance regimes to consider for (very) high-risk NMIBC and MIBC
-
Topic 19Follow-up surveillance regimes for low-/intermediate-risk NMIBC
-
Topic 20Low- and intermediate-risk NMIBC: surveillance or intravesical therapy?
-
Topic 21Systemic therapy for HER2-positive early breast cancer
-
Topic 22First-line systemic therapy in metastatic renal cell carcinoma
-
Topic 23Systemic therapy for mRCC: second line and beyond
-
Topic 24Adjuvant systemic treatment of luminal A/B early breast cancer in premenopausal women
-
Topic 25Adjuvant systemic treatment of luminal A/B early breast cancer in postmenopausal women
-
Topic 26Management of small renal masses
-
Topic 27Systemic therapy for early stage TNBC
-
Topic 28Local therapy for mRCC
-
Topic 29Radiotherapy for early breast cancer
-
Topic 30Management of HER2+ MBC
-
Topic 31Brain metastases in patients with HER2+ breast cancer
-
Topic 32CDK4/6 inhibitors for everyone? Treatment strategies in HR+ HER2- advanced breast cancer
-
Topic 33Theragnostic testing – choosing the right therapy in mTNBC
-
Topic 34Challenges in high-risk NMIBC